Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel in Patients With Metastatic Gastric Cancer After Failure of First-line Chemotherapy, Phase Ib/II
Phase of Trial: Phase I/II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Paclitaxel (Primary) ; Tremelimumab (Primary)
- Indications Carcinoma; Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Dec 2019 Planned End Date changed from 30 Jun 2019 to 30 Jun 2021.
- 02 Dec 2019 Planned primary completion date changed from 30 Jun 2019 to 30 Jun 2021.
- 27 Nov 2018 New trial record